Analysis of Expression of Specific Markers in Hepatocellular Carcinoma
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Other: Retrospective analysis of already archived samples
- Registration Number
- NCT00858000
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these. As a first step in the development of novel therapies, expression analysis of specific markers, including tumor antigens will be carried out. This will be done retrospectively using available hepatocellular carcinoma tissue samples.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- The patient had pathologically proven hepatocellular carcinoma
- All the data required are available from patient's records
- A sufficient amount of RNA is available for all three tissue samples
Exclusion Criteria
N/A
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Group A Retrospective analysis of already archived samples No intervention
- Primary Outcome Measures
Name Time Method Proportion of hepatocellular carcinoma cancer patients whose tumor tissue -expresses any one or more of specific target antigens -overexpresses c-MET -expresses a pre-defied gene-expression signature At the time of analysis. This study will also analyze whether this gene-expression signature is present in matched cirrhotic tissue and the interface tissue with the tumor. At the time of analysis.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
GSK Investigational Site
🇮🇹Firenze, Toscana, Italy